Rafael Holdings, Inc. (RFL) stock
RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
$0.91−0.06 (-5.84%)
Close on Nov 17, 2026Market cap $47.67MP/E –Yield –
Rafael r&d expenses
Research and development expenses are spending on new products and technology.
Rafael's R&D Expenses for the twelve months ending Jul 31, 2026 was $24.33M, up 89.8% year over year. For fiscal 2026 it was $24.33M, up 89.8% from the year before. The highest annual figure on record is $24.33M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $24.33M | +89.8% |
| FY2025 | Jul 31, 2025 | $12.82M | +207.5% |
| FY2024 | Jul 31, 2024 | $4.17M | -33.9% |
| FY2023 | Jul 31, 2023 | $6.31M | -27.8% |
| FY2022 | Jul 31, 2022 | $8.74M | +78.2% |
| FY2021 | Jul 31, 2021 | $4.91M | +105.2% |
| FY2020 | Jul 31, 2020 | $2.39M | +132.8% |
| FY2019 | Jul 31, 2019 | $1.03M | +3.2% |
| FY2018 | Jul 31, 2018 | $995.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $7.47M | +3118.5% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $4.85M | +61.6% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $4.53M | +378.2% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $7.48M | +464.4% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $232.00K | -85.0% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $3.00M | +96.8% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $947.00K | +54.7% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $1.33M | +171.2% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $1.54M | +21.9% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $1.53M | +106.2% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $612.00K | -72.5% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $489.00K | -76.5% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $1.27M | -31.2% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $740.00K | -47.6% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $2.23M | -33.3% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $2.08M | -3.3% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $1.84M | +17.9% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $1.41M | +12.0% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $3.34M | +112.7% |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | $2.15M | +318.1% |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $1.56M | +46.8% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | $1.26M | +99.1% |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | $1.57M | +250.0% |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | $515.00K | +110.2% |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $1.06M | +1264.1% |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | $634.00K | +111.3% |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | $448.00K | +62.3% |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | $245.00K | -34.3% |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | $78.00K | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | $300.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | $276.00K | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | $373.00K | – |
See a number that looks wrong?